All In Biotech

Drug Trial Radar · NCT06517693

Safety and Pharmacokinetics Study of PGT121.414.LS Alone and in Combination With VRC07-523LS in Infants Exposed to HIV-1

Open-Label, Phase I Study of the Safety and Pharmacokinetics of PGT121.414.LS Alone and in Combination With VRC07-523LS in Infants Exposed to HIV-1

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Jan 5, 2026

Primary completion

Nov 30, 2027

Study completion May 31, 2029

Sponsor

Sponsor type
NIH
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute of Mental Health (NIMH)
First posted
Jul 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, up to 72 hours
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of the potent, broadly neutralizing anti-HIV monoclonal antibodies (mAb) PGT121.414.LS alone and in combination with VRC07-523LS soon after birth in infants exposed to HIV-1.

Conditions

  • HIV-1

Interventions

  • PGT121.414.LSDrug

    Administered SC in the thigh

  • VRC07-523LSDrug

    Administered SC in the thigh

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of infants with at least one Grade 3 or higher Adverse Event (AE) (one dose)Time frame: Day 0 through Week 12
  2. Proportion of infants with at least one Grade 3 or higher AE assessed as related to study product (one dose)Time frame: Day 0 through Week 12
  3. Proportion of infants with at least one Grade 3 or higher AE (two doses)Time frame: Day 0 through Week 24
  4. Proportion of infants with at least one Grade 3 or higher AE assessed as related to study product (two doses)Time frame: Day 0 through Week 24
  5. PGT121.414.LS maximum concentration (Cmax) (single/first dose)Time frame: Day 0 through Week 48
  6. PGT121.414.LS time of maximum concentration (Tmax) (single/first dose)Time frame: Day 0 through Week 48
  7. PGT121.414.LS area under the curve (AUC(0-12WK)) (single/first dose)Time frame: Day 0 through Week 12
  8. PGT121.414.LS concentration at the end of the first dose interval (C(12WK)) (single/first dose)Time frame: Week 12
  9. PGT121.414.LS concentration at the end of the second dose interval (C(24WK)) (two doses)Time frame: Week 24
  10. VRC07-523LS maximum concentration (Cmax) (single/first dose)Time frame: Day 0 through Week 48
  11. VRC07-523LS time of maximum concentration (Tmax) (single/first dose)Time frame: Day 0 through Week 48
  12. VRC07-523LS area under the curve (AUC(0-12WK))Time frame: Day 0 through Week 12
  13. VRC07-523LS concentration at the end of the first dose interval (C(12WK)) single/first dose)Time frame: Week 12
  14. VRC07-523LS concentration at the end of the second dose interval (C(24WK)) (two doses)Time frame: Week 24

Locations

19 sites in 6 countries. Site status is shown where the registry gives one.

  • Site 5112, David Geffen School of Medicine at UCLA

    Los Angeles, California · Not yet recruiting

  • Site 5052, University of Colorado Denver NICHD CRS

    Aurora, Colorado · Recruiting

  • Site 5051, University of Florida Jacksonville NICHD CRS

    Jacksonville, Florida · Recruiting

  • Site 32512, Pediatric Perinatal HIV CRS

    Miami, Florida · Not yet recruiting

  • Site 5127, Pediatric Perinatal HIV

    Miami, Florida · Withdrawn

  • Site 5030, Emory University School of Medicine NICHD CRS

    Atlanta, Georgia · Not yet recruiting

  • Site 32515, Rush Univ./Cook County Hosp. Chicago CRS

    Chicago, Illinois · Not yet recruiting

  • Site 5083, Rush University Cook County Hospital Chicago

    Chicago, Illinois · Withdrawn

  • Site 5092, Johns Hopkins University Baltimore

    Baltimore, Maryland · Recruiting

  • Site 5114, Bronx-Lebanon Hospital Center

    The Bronx, New York · Recruiting

  • Site 5013, Jacobi Med. Ctr Bronx NICHD CRS

    The Bronx, New York · Not yet recruiting

  • Site 6501, St. Jude Children's Research Hospital CRS

    Memphis, Tennessee · Not yet recruiting

  • Site 5128, Baylor College of Medicine/Texas Children's Hospital NICHD CRS

    Houston, Texas · Recruiting

  • Site 5097, Hospital Geral De Nova Iguacu Brazil NICHD CRS

    Rio de Janeiro, Brazil · Not yet recruiting

  • Site 5072, Hospital Federal dos Servidores do Estado

    Rio de Janeiro, Brazil, Brazil · Withdrawn

  • Site 5121, Kenya Medical Research Institute/Walter Reed Project Clinical Research Center, Kericho CRS

    Kericho, Kenya · Recruiting

  • Site 32513, IMPAACT/Gamma Project/UPR Pediatric HIV/AIDS Research Network CRS

    San Juan, Puerto Rico, Puerto Rico · Not yet recruiting

  • Site 8950, FAMCRU

    Cape Town, Parrow Valley, South Africa · Not yet recruiting

  • Site 31890, Harare Family Care CRS

    Harare, Zimbabwe · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.